



NCI-Frederick
Institutional Biosafety Committee

Minutes
October 20, 2009
NCI-Frederick

Introduction

The NCI-Frederick Institutional Biosafety Committee was convened at 12:08 p.m. in the Building 549 Executive Board Room with the following members in attendance:

Dr. Dan McVicar, Chair; Ms. Theresa Bell, IBC Secretary and Biosafety Officer; Dr. Serguei Kozlov;; Mr. Lucien Winegar; Dr. Stephen Hughes; Dr. Michael Baseler; Dr. Eric Freed; Ms. Alberta Peugeot; Mr. Scott Jendrek; Reverend David Betzner

Members not in attendance: Dr. David Garfinkel; Dr. Bruce Crise; Dr. Melinda Hollingshead; Dr. Henry Hearn; Dr. Randall Morin; Dr. Stephen Creekmore; Ms. Dianna Conrad

Others in attendance: Dr. Scott Keimig, Dr. Robert Thomas, Mr. Bill Brady (VCMP)

Dr. McVicar began the meeting on a sad note addressing the sudden passing of an IBC member and NCI-Frederick colleague, Dr. David Derse.

Dr. McVicar announced that a new IBC Administrator, Kimberly DiGiandomenico would be joining SAIC-Frederick and the NCI-F IBC starting on November 2, 2009.

Minutes

There were no minutes reviewed at this meeting.

Accident Reviews

None to report.

Review Of Protocols

NEW IBC REGISTRATIONS

09-52 (Dr. Sterneck) NCI, LCDS

-There were no additional comments on this registration. All lead reviewer comments remain to be addressed by PI.

Dr. Freed made a motion to conditionally approve, Dr. McVicar seconded and all were in favor.

09-53 (06-83) (Dr. Sterneck) *Dox-inducible C/EBPdelta transgenic*

-This is a breeding only registration.

-There were no additional comments on this registration. All lead reviewer comments remain to be addressed by PI.

Dr. Freed made a motion to conditionally approve, Dr. McVicar seconded and all were in favor.

Renewals

None.

Amendments

07-34 (Dr. Hornung) Head, Immunological Monitoring Lab

-Pending PI responses and full-committee review.

All other amendments submitted at this time have been approved.

Outstanding Items

-Updates were provided to the Committee by Ms. Bell.

-The committee made a motion to notify senior management regarding the delay in receipt of an IBC registration to cover work with unknown animal materials. The Laboratory of Genomic Diversity has until October 30, 2009 to submit this registration. If, at that time, no registration has been received, the appropriate management personnel will be notified.

Dr. Betzner made the motion, Dr. Hughes seconded and all were in favor.

Other Business

BBP Compliance: 98%

Human Pathogen Screen Update:

-The human pathogen screening should transition from AHDL to MGD sometime Fall 2009. Updates will be forthcoming.

XMRV:

-There was a comment made regarding the creation of an XMRV working committee, which may be helpful to the IBC when reviewing IBC registration documents involving research with XMRV and materials known or suspected to contain XMRV.

VCMP/VPP Accident Update:

- Mr. Bill Brady, Associate Safety Officer for VCMP, was in attendance at the IBC meeting to address members' concerns regarding the recent adenovirus exposure. A report was posted to sharepoint for review by IBC members. This report provided a summary of additional measures being implemented by VPP to ensure system failures and resultant exposures do not occur in the future.
- The IBC requested a cease and desist order/statement be issued by VCMP that this type of research with infectious material will be stopped until procedures and processes are in place, approved, and visually observed by an IBC sub-committee.
- The IBC requested assurance through visual observation, secondary containment, pressure monitoring equipment, new connections, etc, and a riboflavin demonstration to avoid repeat exposure incidents.
- The IBC requested more details as to how employees will be trained with documentation on new procedures and how failures to communicate accurate and complete information effectively will be corrected.
- An updated employee roster was requested for this IBC registration document.
- IBC requested that SOP's be separated into independent SOP's for development runs and actual client-requested production runs.
- Mr. Brady will also seek guidance from the Biopharmaceutical Development Program.

The meeting was adjourned at 1:00 p.m.

Theresa D. Bell, MPH, CBSP
IBC Secretary
Biological Safety Officer, EHS

Date

APPROVED:

Dan McVicar, Ph.D.
Chairman, NCI-Frederick IBC

Date

xc: Dr. Reynolds
Mr. Ramos
Dr. Arthur
Mr. Bufter